구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Anti-IL17 |
Overview Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Atopic Dermatitis; Psoriasis |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting the IL-17A pathway |
MoA Biomarker | biomarker of immunosuppression |
PK/PD Species | Hamster |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PD |
Toxicology Species | Hamster |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Safety signal | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Program phase | PRECLINICAL |
Preclinical Animal (cat.) | Unknown |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Anti-IL17 |
Overview Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Atopic Dermatitis; Psoriasis |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting the IL-17A pathway |
MoA Biomarker | biomarker of immunosuppression |
PK/PD Species | Hamster |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PD |
Toxicology Species | Hamster |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Safety signal | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Program phase | PRECLINICAL |
Preclinical Animal (cat.) | Unknown |
추천 비교
추천 비교